InhaleRx

InhaleRx is an Australian healthcare company focused on developing specialized inhalation therapies for medicinal cannabis-derived drug candidates. The company targets unmet medical needs in pain management and mental health, specifically focusing on breakthrough cancer pain and panic disorder. By utilizing precision-metered dose inhalers (MDIs), InhaleRx aims to provide a rapid onset of action and highly consistent dosing compared to traditional oral or sublingual delivery methods. The firm is currently advancing its lead candidates, IRX211 and IRX616, through the clinical trial process to establish safety and efficacy for regulatory approval. Headquartered in Melbourne, InhaleRx is publicly traded on the Australian Securities Exchange.